

## FORM 7

### MONTHLY PROGRESS REPORT

**Name of Listed Issuer:** The Yield Growth Corp. (the “**Issuer**”).

**Trading Symbol:** BOSS

**Number of Outstanding Listed Securities:** 109,259,810 common shares (plus 47,160,373 common shares reserved for issuance in the form of 30,020,379 warrants, 1,816,666 special warrants, and 15,323,328 options)

**Date:** January 1, 2020

#### **Report on Business**

1. **Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On December 2, 2019, the Issuer’s subsidiary, Yield Botanicals Inc., entered into a non-binding LOI to acquire Canniva Capital Inc. (“**Canniva**”), which is developing CBD assets in Europe. The proposed terms of the acquisition are that Yield Botanicals will acquire all of the issued and outstanding shares of Canniva by issuing one common share and one share purchase warrant in Yield Botanicals to acquire each share of Canniva. The proposed acquisition is subject to Canniva raising \$1,000,000 at \$0.10 per common share. Once the acquisition is complete, Yield Botanicals has an obligation to go public and obtain a stock exchange listing either by Initial Public Offering or by reverse merger with a listed company within six (6) months. Upon listing the Issuer is expected to own 50,000,000 common shares and 70% of the listed entity.

On December 5, 2019, the Issuer’s subsidiary, Flourish Mushroom Labs Inc. (“**Flourish**”), started initial consumer tasting trials for four organic mushroom coffees using a unique blend of freshly ground coffee beans and various mushroom formulations.

On December 10, 2019, Flourish filed a US provisional patent application in the United States for the invention relating to methods of using serotonin antagonists, in particular, psychedelic mushroom actives, for weight loss. The pending patent seeks to protect the invention that administration of psilocin and/or psilocybin results in an overall weight loss in individuals by reducing food cravings, counteracting compulsive overeating, and aiding in improving quality of diet by altering food choices. The patent pending covers the use of microdose administration of psilocin/psilocybin to have the additional weight loss effect of increasing metabolism, which combined with a decrease in food cravings or compulsive overeating, or altering food choices to less calorie dense foods, could result in substantial and beneficial weight loss. The pending patent also covers the use of psilocin/psilocybin in treatment or regulation of diabetes, and regulation of blood glucose and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, and other illnesses associated with obesity.

On December 12, 2019, the Issuer announced that manufacturing was complete on five (5) SKU's of the Wright & Well THC and CBD product line. The products are expected to be available in retailers in Oregon in January 2020, capitalizing on the opportunity presented by the US market.

On December 17, 2019, the Issuer announced the website to support sales of Wright & Well topical products in the state of Oregon launched at [www.wrightandwellplus.com](http://www.wrightandwellplus.com).

**2. Provide a general overview and discussion of the activities of management.**

Please see Item 1 above.

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

Please see Item 1 above.

**4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

**5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

Please see Item 1 above.

**6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

**7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

Please see Item 1 above.

**8. Describe the acquisition of new customers or loss of customers.**

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Please see Item 1 above.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

A former employee started a small claims action against the Company. An agreement was reached between the parties and the Company settled. A Notice of Withdrawal has been filed by the former employee.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Special Warrants	1,262,500	December 6, 2019: 1,262,500 special warrants issued pursuant to a private placement at a price of \$0.20 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on December 10, 2019	Net proceeds of \$252,500 to be used as set out in the Prospectus Supplement.
Stock Options	198,000	December 9, 2019: 198,000 stock options granted to various employees and consultants at an exercise price of \$0.245 per common share for a maximum period of 5 years (or earlier in	Not applicable

		accordance with the Issuer's stock option plan)	
Units	1,262,500	December 13, 2019: 1,262,500 units issued pursuant to the conversion of the special warrants issued on December 6, 2019. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.25 until June 6, 2020.	
Special Warrants	1,731,291	December 20, 2019: 1,731,291 special warrants issued pursuant to a private placement at a price of \$0.25 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on December 30, 2019	Net proceeds of \$432,822.80 to be used as set out in the Prospectus Supplement.
Units	1,000,000	December 31, 2019: 1,000,000 units issued at a price of \$0.25 per unit. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.265 until December 31, 2020.	Net proceeds of \$250,000 to be used for a one year contract for marketing services.

(1) State aggregate proceeds and intended allocation of proceeds.

**15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

Please see item 1 above.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On October 17, 2018, The Cannabis Act came into force in Canada and recreational cannabis is now available to legal adults (aged 18 or 19 depending on the province or territory) for purchase, growth, or use in limited quantities. On October 17, 2019, additional legislation came into force in Canada allowing and regulating the use and sale of Cannabis topical and edible products.

## **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

**Dated** January 1, 2020.

Penny White  
Name of Director or Senior Officer

"Penny White"  
Signature

Chief Executive Officer and  
President  
Official Capacity

<b>Issuer Details</b> <b>Name of Issuer</b> The Yield Growth Corp.	<b>For Month End</b> December 2019	<b>Date of Report</b> <b>YY/MM/DD</b> 20/01/01
<b>Issuer Address</b> Suite 200, 1238 Homer Street		
<b>City/Province/Postal Code</b> Vancouver, British Columbia V6B 2Y5	<b>Issuer Fax No.</b> N/A	<b>Issuer Telephone No.</b> 833.514.2677
<b>Contact Name</b> Penny White	<b>Contact Position</b> President, CEO, and Director	<b>Contact Telephone No.</b> 833.514.2677
<b>Contact Email Address</b> <a href="mailto:penny@yieldgrowth.com">penny@yieldgrowth.com</a>	<b>Web Site Address</b> <a href="http://www.yieldgrowth.com">www.yieldgrowth.com</a>	